China Biotech Services Holdings Limited provided unaudited consolidated earnings guidance for the nine months ended September 30, 2018. For the period, the company expects to record a net loss of not less than HKD 46,000,000 for the 2018 third quarter Period as compared to the net loss of approximately HKD 15,152,000 recorded for the corresponding period in 2017. The increase in net loss for the 2018 third quarter Period was mainly attributable to amortisation of equity-settled share-based payment of approximately HKD 9,931,000 in relation to the granting of share options (as opposed to the absence of such amortisation for the corresponding period in 2017). Increase in administrative expenses (excluding amortisation of equity-settled share-based payment) of approximately HKD 12,455,000; and neither a gain on disposal of associates and subsidiaries nor gain or loss on fair value change of financial assets at fair value through profit or loss would be recorded (as opposed to a gain on disposal of associates and subsidiaries of approximately HKD 28,031,000 being recorded which was partially offset by a net loss of approximately HKD 22,185,000 on financial assets at fair value through profit or loss for the corresponding period in 2017).